Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Neuroimaging Technique Identifies Patients at Risk for Alzheimer's Disease in Healthy Brains

By LabMedica International staff writers
Posted on 28 Dec 2009
Brain imaging can offer a window into risk assessment into for diseases such as Alzheimer's disease (AD). More...
A recent study demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD.

The results of this study were published in the November 2009 issue of the Journal of Alzheimer's Disease. Investigators used automated neuroimaging analysis with voxel-based magnetic resonance (MRI) imaging diffusion tensor imaging (DTI) techniques to characterize the impact of an AD-risk gene, apolipoprotein E (ApoE4), on gray and white matter in the brains of cognitively healthy elderly from the KU [University of Kansas] Brain Aging Project.

The investigators discovered that healthy elderly individuals carrying a risk-allele of the ApoE4 gene had reduced cognitive performance, decreased brain volume in the hippocampus, and amygdala (regions important for memory processing), and decreased white matter integrity in limbic regions. These types of brain changes are also found in people with AD. Therefore, brain changes, typically found in AD patients, are also evident in nondemented individuals who have a genetic risk of later developing AD.

Lead investigator, Robyn Honea, D.Phil., research assistant professor, University of Kansas School of Medicine (Wichita, USA), department of neurology, Alzheimer's and Memory Group, commented, "It is important to note that findings of imaging phenotypes of risk variants, such as with this gene, have been shown in a number of studies. The unique element of our study is that we used several new neuroimaging analysis techniques. In addition, the individuals in our study have been well-characterized in a clinical setting.”

This research was conducted in the laboratory of Jeffrey M. Burns, M.D., associate professor in the department of neurology at the University of Kansas Medical Center. He is the director of the Alzheimer and Memory Center and the Alzheimer's Disease Clinical Research Program. Dr. Burns serves as the lead investigator of the Brain Aging Program.

Related Links:

University of Kansas School of Medicine




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.